San Diego, CA 7/9/2009 11:09:46 PM
AMAG Pharmaceuticals' Feraheme Monkey Off Its Back - Analysis at SmallCapNetwork.com
Now that the anemia treatment Feraheme has been approved by the FDA, AMAG Pharmaceuticals, Inc. (AMAG) is ready to switch into sales mode.
AMAG Pharmaceuticals, Inc. (AMAG) is gearing up to start selling Feraheme, the company's recently-approved anemia drug for kidney disease patients. AMAG Pharmaceuticals will initially market the drug through wholesalers and distributors. Feraheme should be available later this month.
Investors and traders are invited to read further analytical review of AMAG Pharmaceuticals, Inc. as well as similar opportunities by subscribing to the free Small Cap Network Newsletter, which offers complete access to all commentary, market trend analysis, trading ideas and other useful market related insights by going to: www.smallcapnetwork.com/s/.
Feraheme is expected to be attractive because it is simpler to use than current alternatives. The injection only last a few seconds, where other iron-based treatments take much longer because they require an infusion. Moreover, the next -nearest comparable drug - Venofer - is administered about once every three days. AMAG Pharmaceuticals' Feraheme only requires about one injection per week. AMAG Pharmaceuticals has also requested European approval for Feraheme.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. (AMAG) is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. For additional company and product information please visit www.amagpharma.com.
Forward-Looking Statement: This press release may include or imply "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Small Cap Network is not a registered investment advisers or broker/dealer. Small Cap Network makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for many of their securities, investing in such securities is highly speculative and carries a high degree of risk.
Contact Information:
Small Cap Network
4653 Carmel Mtn. Rd
Suite 308 #402
San Diego, CA 92130
Email: editor@smallcapnetwork.com
Source: Small Cap Network
http://community.smallcapnetwork.com/Four-Small-Cap-Biotechs-FDA-Favors-Two-Denies-Two/s/article/view/p/mid/1/id/134/
